Non-Invasive Cancer Diagnostics Market Forecasts to 2028 – Global Analysis By Therapeutics (Lung Cancer, Breast Cancer, Solid Tumors and Other Therapeutics), By Technology (Clinical Chemistry, Spectroscopy, Immunoassay and Other Technologies), By End User

Non-Invasive Cancer Diagnostics Market Forecasts to 2028 – Global Analysis By Therapeutics (Lung Cancer, Breast Cancer, Solid Tumors and Other Therapeutics), By Technology (Clinical Chemistry, Spectroscopy, Immunoassay and Other Technologies), By End User (Hospitals & Clinics, Ambulatory Care and Other End Users) and Geography

According to Stratistics MRC, the Global Non-Invasive Cancer Diagnostics Market is accounted for $114.23 billion in 2022 and is expected to reach $191.57 billion by 2028 growing at a CAGR of 9.0% during the forecast period. Cancer is a complex medical condition for which no effective treatment has yet been discovered. Non-invasive cancer diagnostics are procedures that identify cancer problems with minimal body incision. Cancer is a disease that is caused by a genetic change in the cells, which leads to uncontrolled growth and the formation of a tumor like structure. Although imaging is the preferred method of cancer detection, it does not allow for genetic access. Biopsies that allow for genetic access, on the other hand, are complex and difficult to perform repeatedly during cancer diagnosis and treatment. Non-invasive cancer diagnostics are becoming more important than traditional cancer diagnosis due to the rise in the occurrence of chronic cancers such as breast cancer and lung cancer.

According to the World Health Organization and the World Cancer Survey, approximately 15 million new cancer cases will be diagnosed each year by 2020, with breast, ovarian, and gastrointestinal cancers being the most common. Because of the traumatic experience and inefficiency of existing procedures, new non-invasive cancer diagnostics with advanced approaches have gained popularity, propelling Non-Invasive cancer diagnostics market growth.

Market Dynamics:

Driver:

Rising prevalence of cancer

Cancer has a huge social impact all over the world. It is one of the leading causes of death worldwide, with a higher prevalence in developed and emerging markets. The concerning trend of rising cancer prevalence prompts healthcare providers to reconsider their treatment goals and place a greater emphasis on prevention. This would necessitate cancer diagnostics that are not only specific and sensitive but also capable of detecting and treating cancer at an early stage. Non-invasive cancer diagnosis employs techniques such as identifying genetic structure, biomarkers, and changes in molecular biology and imaging technology.

Restraint:

High Cost of Treatment and stringent regulations

High treatment costs and stringent regulatory rules limit the global non-invasive cancer diagnostics market. The market for non invasive cancer diagnostics in developing and emerging countries is hesitant to adopt these expensive devices, posing a challenge to the market. The development of an effective diagnostic with adequate sensitivity and specificity for the early detection of lung cancer, particularly the detection of circulating tumor DNA present in smaller amounts, presents significant challenges hindering market growth.

Opportunity:

Rising Technological Advancements

Rapid technological advancements and device innovation are expected to create lucrative growth opportunities. Increased government initiatives to improve healthcare diagnostics and technology are expected to drive market growth in the coming years. Furthermore, medical tourism is increasing in developing economies such as China and India, which aids market expansion. People are becoming more aware of the advantages of early cancer detection and treatment, which has resulted in an increase in the number of people receiving a diagnosis.

Threat:

Low biomarker discovery-to-approval ratio

Thousands of candidate biomarkers have been identified as a result of research. Despite recent advances in biomarkers, a lack of clarity about several basic elements prevents biomarkers from reaching their full potential in human medicine. One of the major challenges is the lack of acceptance of robust clinical biomarker tests. Biomarkers identified in early discovery studies do not always show reproducible activity during subsequent validation. Existing biomarkers are insufficient and frequently lack specificity, while new biomarkers are being developed slowly. As a result, better biomarkers are required to improve diagnosis, guide molecularly targeted therapy, and monitor activity and therapeutic response in various cancer types.

Covid-19 Impact

COVID-19 had a negative impact on the market for non-invasive cancer diagnostics in 2020. The implementation of lockdowns due to the COVID-19 outbreak delayed cancer diagnosis. It also had an impact on the logistics and supply of cancer detection equipment or products. National lockdowns, government regulations, and an increase in infection rates across countries all had a significant financial impact on cancer hospitals and outpatient clinics. Several hospitals and clinics reported a decrease in patient visits during COVID-19, ultimately reducing client contact. Furthermore, the pandemic caused a delay in several cancer diagnostic procedures and non-invasive cancer treatments. Another factor limiting the cancer diagnostics market was a limited availability of healthcare personnel.

The Breast Cancer segment is expected to be the largest during the forecast period

Breast Cancer segment is estimated to be the largest throughout the forecast period. This can be attributed to an increase in global breast cancer incidence as well as an increase in the population of women aged 50 to 74. The segment is expected to grow in the coming years as a result of an increase in initiatives by various organisations for early breast cancer screening and diagnosis. Factors such as the rapid increase in the number of breast cancer cases worldwide and the improvement of the healthcare sector are driving the segment forward.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is expected to register the highest CAGR during the forecast period due to an increase in the number of hospitals and an increase in non-invasive cancer diagnostic procedures in this setting.The increased number of hospitals in the region has resulted in an increase in the number of cancer diagnostic tests performed. Furthermore, rapid technological advancements and device innovations are anticipated to create market-beneficial opportunities for the Hospitals and Clinics segment, which drives market growth.

Region with largest share:

North America has the largest market share in the Non-Invasive cancer diagnostics market due to the region's well-developed healthcare infrastructure, high per capita healthcare expenditure, high awareness, and high literacy rate. The mortality rate of cancer patients is decreasing in the United States, and one of the major factors responsible for this is early diagnosis. The large presence of medical devices and biotechnology firms in the region, as well as the presence of skilled technicians, are some of the major influencers for market growth in the region. High research and development, as well as large funding options, are a few other factors driving market growth.

Region with highest CAGR:

The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, owing to an increase in awareness of minimally invasive equipment in the region, which has contributed to market growth. On the other hand, the region's market is thriving as a result of medical tourism, increased awareness, and investment in private diagnostic centers. During the forecast period, the region's market is expected to benefit from an increase in the geriatric population, an increase in cancer incidence, and increased awareness about non-invasive equipment for cancer diagnosis. Moreover, the governments of Japan, China, and India fund and support universities and research institutes in order to develop new cancer diagnostic technologies. This is propelling the region's market for non-invasive cancer diagnostics.

Key players in the market

Some of the key players profiled in the Non-Invasive Cancer Diagnostics Market include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Dr Lal PathLabs Ltd., Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical, Roche Holding AG, Affymetrix Inc, Subtle Pharmaceuticals Pvt. Ltd. and Precision Therapeutics.

Key Developments:

In July 2022, Unilabs Sweden partnered with Subtle Medical, a healthcare technology company using artificial intelligence for faster and higher quality MRI, to improve the quality and efficiency of their MRI imaging. Subtle Medical's SubtleMR would assist radiologists in performing high-quality imaging more efficiently.

In May 2019, Roche Diagnostics introduced the first in vitro diagnostic immunohistochemistry (IHC) assay in 2019 to improve lung cancer diagnosis.


Therapeutics Covered:
• Lung Cancer
• Breast Cancer
• Solid Tumors
• Blood Cancer
• Other Therapeutics

Technologies Covered:
• Clinical Chemistry
• Spectroscopy
• Immunoassay
• Molecular Diagnostics
• Other Technologies

End Users Covered
• Hospitals & Clinics
• Ambulatory Care
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements